{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:47:09Z","timestamp":1769604429758,"version":"3.49.0"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Continuum"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1212\/01.con.0000443836.18131.c9","type":"journal-article","created":{"date-parts":[[2014,2,4]],"date-time":"2014-02-04T02:37:59Z","timestamp":1391481479000},"page":"42-59","source":"Crossref","is-referenced-by-count":12,"title":["Multiple Sclerosis in Pregnancy"],"prefix":"10.1212","volume":"20","author":[{"given":"Patricia K.","family":"Coyle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_1_20_2","doi-asserted-by":"crossref","unstructured":"Cutter G Salter A. Got milk? Ann Neurol 2011; 70 (1): 3\u20134.","DOI":"10.1002\/ana.22507"},{"key":"e_1_3_1_26_2","doi-asserted-by":"crossref","unstructured":"Teter B Kavak KS Kolb C et al. Parity associated with long-term disease progression in women with multiple sclerosis. Presented at: 65th Annual Meeting of the American Academy of Neurology; March 2013; San Diego CA.","DOI":"10.4172\/jmso.1000101"},{"key":"e_1_3_1_28_2","unstructured":"Adapted from Womenshealth.gov. Office on Women\u2019s Health US Department of Health and Human Services. Birth Control Methods. www.womenshealth.gov\/publications\/our-publications\/fact-sheet\/birth-control-methods.pdf. Accessed November 26 2013."},{"key":"e_1_3_1_32_2","doi-asserted-by":"crossref","unstructured":"Tomczyk S Sperling B. Pregnancy outcomes in patients exposed to intramuscular interferon beta-1a (IM IFN\u03b2-1a) (S30.006). AAN 2013 Annual Meeting.","DOI":"10.1212\/WNL.80.7_supplement.S30.006"},{"key":"e_1_3_1_37_2","doi-asserted-by":"crossref","unstructured":"Cristiano L Friend S Bozic C et al. Evaluation of pregnancy outcomes from the TYSABRI (natalizumab) pregnancy exposure registry. Presented at: 65th Annual Meeting of the American Academy of Neurology; March 2013; San Diego CA.","DOI":"10.1212\/WNL.80.7_supplement.P02.127"},{"key":"e_1_3_1_38_2","unstructured":"Haghikia A Bochum G Rolfes E et al. Natalizumab in active MS during pregnancy: efficacy safety and the consequences for fetal hematopoiesis. Presented at: 65th Annual Meeting of the American Academy of Neurology; March 2013; San Diego CA."},{"key":"e_1_3_1_39_2","unstructured":"Geissbuhler Y Butzkueven H Hernandez-Diaz S et al. Pregnancy outcomes from fingolimod clinical trials and post-marketing experience and the need for a multinational Gilenya (fingolimod) pregnancy exposure registry in multiple sclerosis. Presented at: 28th Annual Meeting of the European Committee for Treatment and Research in Multiple Sclerosis."},{"key":"e_1_3_1_42_2","doi-asserted-by":"crossref","unstructured":"Henson LJ Stuve O Kieseler B et al. Pregnancy outcomes from the Teriflunomide clinical development program: retrospective analysis of the Teriflunomide clinical trial database. Presented at: 65th Annual Meeting of the American Academy of Neurology; March 2013; San Diego CA.","DOI":"10.1212\/WNL.80.7_supplement.S30.005"},{"key":"e_1_3_1_43_2","doi-asserted-by":"crossref","unstructured":"Gold R Bochum G Phillips T et al. BG-12 (dimethyl fumarate) and pregnancy: preclinical and clinical data from the clinical development program. Presented at: 65th Annual Meeting of the American Academy of Neurology; March 2013; San Diego CA.","DOI":"10.1212\/WNL.80.7_supplement.P02.129"},{"key":"e_1_3_1_49_2","doi-asserted-by":"crossref","unstructured":"Langer-Gould A Beaber BE. Effects of pregnancy and breastfeeding on the multiple sclerosis disease course. Clin Immunol 2013.doi:10.1016\/j.clim.2013.01.008.","DOI":"10.1016\/j.clim.2013.01.008"},{"key":"e_1_3_1_54_2","unstructured":"Vukusic S El-Etr M Ionescu I et al. The POPARTMUS French-Italian multicentric trial of post partum progestin and estriol in multiple sclerosis; final results. Presented at: 28th Annual Meeting of the European Committee for Treatment and Research in Multiple Sclerosis."}],"container-title":["Continuum"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/continuum\/Fulltext\/10.1212\/01.CON.0000443836.18131.c9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T14:03:42Z","timestamp":1752156222000},"score":1,"resource":{"primary":{"URL":"https:\/\/continuum.aan.com\/doi\/10.1212\/01.CON.0000443836.18131.c9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["10.1212\/01.CON.0000443836.18131.c9"],"URL":"https:\/\/doi.org\/10.1212\/01.con.0000443836.18131.c9","relation":{},"ISSN":["1080-2371","1538-6899"],"issn-type":[{"value":"1080-2371","type":"print"},{"value":"1538-6899","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}